Alexander M. Eggermont, MD, PhD, on Melanoma: Pembrolizumab vs Placebo After Complete Resection
ESMO Virtual Congress 2020
Alexander M. Eggermont, MD, PhD, of the Princess Maxima Center for Pediatric Oncology, discusses final results of the phase III EORTC 1325-MG/Keynote 054 trial, which confirmed a sustained recurrence-free survival benefit of pembrolizumab vs placebo in patients with resected high-risk stage III melanoma, as well as a decrease in the incidence of distant and locoregional recurrence (Abstract LBA46).
The ASCO Post Staff
Erica L. Mayer, MD, MPH, of Dana-Farber Cancer Institute, discusses an initial analysis of phase III findings from the PALLAS trial, which suggested the benefits observed in the metastatic setting with palbociclib plus endocrine therapy did not translate into the earlier adjuvant setting for patients with hormone receptor–positive, HER2-negative breast cancer. Long-term follow-up is ongoing (Abstract LBA12).
The ASCO Post Staff
Jeffrey S. Weber, MD, PhD, of the Perlmutter Cancer Center, NYU Langone, discusses the 4-year recurrence-free and overall survival results from the CheckMate 238 study, which showed adjuvant nivolumab continues to be an effective treatment, vs the comparator ipilimumab, for patients with resected stage III/IV melanoma (Abstract 1076O).
The ASCO Post Staff
Erika P. Hamilton, MD, of Sarah Cannon Research Institute, discusses results of the nextMONARCH study, which indicated that combining abemaciclib with tamoxifen improved overall survival. Dr. Hamilton also details adverse events in different arms of the study (Abstract 273O).
The ASCO Post Staff
Andreas du Bois, MD, PhD, of Kliniken Essen Mitte, discusses the NORA and INOVATYON studies of patients with recurrent ovarian cancer, detailing the findings for women in China with platinum-sensitive disease and women internationally who received trabectedin and pegylated liposomal doxorubicin (PLD) followed by platinum at disease progression vs carboplatin and PLD after disease progression (Abstract LBA29 and LBA30).
The ASCO Post Staff
Cécile Le Pechoux, MD, of the Institut Gustave Roussy, discusses new findings from an international trial on an old controversy: What is the role of postoperative radiotherapy in locally advanced (stage III) non–small cell lung cancer? The researchers enrolled patients with completely resected disease and mediastinal N2 involvement (Abstract LBA3).
